# MMR/MSI in gastric and GEJ adenocarcinoma

1 EU-approved indication in gastric and GEJ adenocarcinoma needs a MMR/MSI result: pembrolizumab (2nd line, advanced).

## Approved indications

### dMMR / MSI-H

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Pembrolizumab](https://oncolabels.com/drugs/pembrolizumab) (Keytruda) | MMR/MSI deficient | Monotherapy | 2nd line, advanced | Disease progression on or following at least one prior therapy |

## Label wording

- **Pembrolizumab** (Keytruda), Gastric and GEJ adenocarcinoma, 2nd line, advanced: “unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/tumours/gastric-and-gej-adenocarcinoma/mmr-msi